Evolus Inc (NASDAQ:EOLS) — Market Cap & Net Worth
Market Cap & Net Worth: Evolus Inc (EOLS)
Evolus Inc (NASDAQ:EOLS) has a market capitalization of $522.46 Million ($522.46 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12036 globally and #3037 in its home market, demonstrating a -14.95% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Evolus Inc's stock price $7.91 by its total outstanding shares 66050440 (66.05 Million). Also see EOLS total asset value for a full breakdown of the balance sheet.
Evolus Inc Market Cap History: 2018 to 2026
Evolus Inc's market capitalization history from 2018 to 2026. Data shows change from $786.00 Million to $522.46 Million (-4.26% CAGR). Also see EOLS cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Evolus Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.02% | #334 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #1205 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.03% | #186 of 263 |
Weight: Evolus Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Evolus Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Evolus Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Evolus Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.48x
Evolus Inc's market cap is 1.48 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $803.83 Million | $34.92 Million | -$90.03 Million | 23.02x | N/A |
| 2020 | $221.93 Million | $56.54 Million | -$163.01 Million | 3.93x | N/A |
| 2021 | $429.99 Million | $99.67 Million | -$46.81 Million | 4.31x | N/A |
| 2022 | $496.04 Million | $148.62 Million | -$74.41 Million | 3.34x | N/A |
| 2023 | $695.51 Million | $202.09 Million | -$61.69 Million | 3.44x | N/A |
| 2024 | $729.20 Million | $266.27 Million | -$50.42 Million | 2.74x | N/A |
| 2025 | $439.24 Million | $297.18 Million | -$51.64 Million | 1.48x | N/A |
Competitor Companies of EOLS by Market Capitalization
Companies near Evolus Inc in the global market cap rankings as of September 17, 2026. Review Evolus Inc tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Evolus Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Evolus Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Evolus Inc's market cap moved from $786.00 Million to $ 522.46 Million, with a yearly change of -4.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $522.46 Million | +18.95% |
| 2025 | $439.24 Million | -39.76% |
| 2024 | $729.20 Million | +4.84% |
| 2023 | $695.51 Million | +40.21% |
| 2022 | $496.04 Million | +15.36% |
| 2021 | $429.99 Million | +93.75% |
| 2020 | $221.93 Million | -72.39% |
| 2019 | $803.83 Million | +2.27% |
| 2018 | $786.00 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Evolus Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $522.46 Million USD |
| MoneyControl | $522.46 Million USD |
| MarketWatch | $522.46 Million USD |
| marketcap.company | $522.46 Million USD |
| Reuters | $522.46 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Evolus Inc
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels,… Read more